Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6432836

Cc1ccccc1CN(CC(=O)O)S(=O)(=O)c1ccc2c(N(Cl)C(=N)N)cncc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.39
KEAP1 Q14145 4/20 0.39
TAS2R14 Q9NYV8 2/20 0.37
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 1/20 0.34
DAGLA Q9Y4D2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
PTPN1 P18031 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6437830 0.90 KEAP1 (0.42) PLAUKEAP1TAS2R14LMNASMN1; SMN2
Trifluoroacetic Acid SCHEMBL6435141 0.90 PLAU (0.49) PLAUKEAP1DAGLAALDH1A1MMP1
SCHEMBL6436322 0.86 NR1D1 (0.37) PLAUKEAP1TAS2R14LMNAHTT
Trifluoroacetic Acid SCHEMBL6434437 0.85 PLAU (0.46) PLAUTAS2R14LMNAMAPTDAGLA
Trifluoroacetic Acid SCHEMBL6432736 0.84 PLAU (0.46) PLAUKEAP1MAPTALDH1A1GAA
Trifluoroacetic Acid SCHEMBL6433676 0.83 PLAU (0.48) PLAUKEAP1
Trifluoroacetic Acid SCHEMBL7371647 0.83 ALDH1A1 (0.39) PLAUKEAP1TAS2R14LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL7366869 0.82 PLAU (0.41) PLAUKEAP1DAGLAALDH1A1GAA
SCHEMBL7377717 0.81 PLAU (0.45) PLAUKEAP1LMNASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL6433236 0.81 PLAU (0.44) PLAUKEAP1LMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885KEAP1 2747/4885TAS2R14 2998/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885KEAP1 2747/4885TAS2R14 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.